CRCT - Cancer Research Center of Toulouse
HomeInvestissements d'Avenir programs at CRCT

Investissements d'Avenir programs at CRCT

 Laboratoire d’Excellence Toulouse Cancer – Labex TOUCAN


The Labex Toucan is composed of eight research teams and coordinates the public teams which are connected to the INSERM, CNRS, and University Paul Sabatier of Toulouse as well as the University Joseph Fourier of Grenoble. Toucan also implies a private research team, Innate Pharma, based in Marseille.

The 5 year long Labex Toucan project is endowed with 5 million euros. It will favor the convergence of research on hematopoietic cancers which attack the blood producing organs, known by general public as leukemia, lymphomas and myelomas cancers. The mechanisms of these pathologies and their strong resistance to treatments still remain unexplained. The structure Labex will allow federating scientific specialties such as mathematics for medicine but also connecting industrial entities as Innate Pharma with public research teams. This will lead to quickly develop patents and clinic applications, essential to patients.

More information on Labex TOUCAN website.

 Pôle de recherche Hospitalo-Universitaire en Cancérologie de Toulouse, PHUC – CAPTOR



More information on PHUC CAPTOR website


 Intertwined roles of NER Factors in transcription and DNA repair Impact of their deregulation in Xeroderma Pigmentosum
01/06/2017- Dr Nicolas Lemay - Salle C. Cazaux - 11:00 - 12:00

 Selective Targeting and Delivery of Therapeutics to Cancer Cells and Tumors Based on the Tumor Microenvironment
29/05/2017 - Dr Damien Thevenin - Salle C. Cazaux - 11:00 - 12:00
Inserm Université Toulouse 3 - Paul Sabatier CNRS